The medtech industry hit further highs in the market last week and the stocks show no sign of stopping their ascent now. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 97.62 (Nov. 6), marking a 7.3% leap from the 91.01 points registered at the […]
NovoCure
Novocure closes $575M offering
NovoCure (NSDQ:NVCR) announced that it closed its previously announced offering of $575 million in 0% convertible senior notes. The notes, due in 2025, are set to bring in net proceeds of approximately $558.4 million after the initial purchasers exercised full their option to purchase an additional $75 million in notes, according to a news release from […]
COVID-19 upends medtech’s financial outlook
The uncertain times brought on by the COVID-19 pandemic have affected businesses worldwide, and several sectors of medtech industry are projecting hits to their bottom lines. A number of companies have announced decisions to withdraw financial guidance, cut hours and/or staff, among other major business decisions. Initial impacts of the global pandemic on Wall Street […]
Novocure’s Optune wins innovative medical device designation from China
NovoCure (NSDQ:NVCR) said today that it was granted Innovative Medical Device Designation in China for its Optune tumor treating system. The Optune system uses electric fields that are tuned in to specific frequencies to disrupt cancer cell division, according to the company. The technology inhibits tumor growth and causes cancer cells to die. Zai Lab has […]
FDA approves Novocure’s NovoTTF-100LTM plus chemo for mesothelioma
NovoCure (NSDQ:NVCR) announced that it has received FDA approval for its NovoTTF-100L system with chemotherapy for treating a type of mesothelioma. NovoTTF-100L is a non-invasive, antimitotic cancer treatment designed to deliver electric fields at special frequencies to disrupt solid tumor cancer cell division. Approved under a humanitarian device exemption, NovoTTF-100L and pemetrexed plus platinum-based chemotherapyis indicated […]
Novocure launches pivotal ovarian cancer trial
Novocure (NSDQ:NVCR) said today that it kicked off a Phase 3 pivotal trial testing its Tumor Treating Fields therapy combined with paclitaxel in people with recurrent, platinum-resistant ovarian cancer. The 540-patient trial has a primary endpoint of overall survival, with secondary endpoints that include progression-free survival, objective response rate, severity and frequency of adverse events and […]
Novocure shares dip on Q4, 2018 earnings miss
Shares in Novocure (NSDQ:NVCR) fell slightly today after the medical device maker missed expectations on Wall Street with its fourth quarter and full year 2018 earnings release. The St. Helier, Jersey-based company posted losses of $15.6 million, or 17¢ per share, on sales of $69.7 million for the three months ended December 31, seeing losses grow […]
Boston Scientific shares tick up after Q4 prelims meet estimates | Wall Street Beat
Shares in Boston Scientific (NYSE:BSX) rose slightly this morning after the company reported preliminary results for the fourth quarter and full year of 2018 that were in-line with estimates on Wall Street. The Marlborough, Mass.-based company said it expects to report $2.56 billion in sales for the fourth quarter and $9.82 billion for the full year. […]
Novocure backs $2m in brain cancer research grants
Novocure (NSDQ:NVCR) today, along with the American Association for Cancer Research, announced four inaugural Tumor Treating Fields research grants totaling more than $1.5 million. The St. Helier, Jersey-based company said that the newly launched grants include the AACR-Novocure Tumor Treating Fields Research Grant, the AACR-Novocure Career Development Award for Tumor Treating Fields Research, the AACR-Novocure Tumor Treating Fields Research Fellowship and […]
Novocure touts analysis of pivotal glioblastoma trial results
Novocure (NSDQ:NVCR) today touted the results of a retrospective sub-group analysis of its EF-14 Phase III pivotal trial in patients with newly diagnosed glioblastoma. The analysis, which was published in the Journal of Neuro-Oncology, demonstrated that more time on Novocure’s Optune device predicted increased survival in people who received Optune plus temozolomide compared to those who received […]
NovoCure slides on Q3 sales miss
NovoCure (NSDQ:NVCR) shares took a hit today, despite lower-than-forecast losses, after the company reported financial results that missed expectations for third-quarter sales. Losses were up 1.7% to -$11.7 million, or -13¢ per share, on sales growth of 29.2% to $64.8 million for the three months ended Sept. 30, compared with Q3 2017. The consensus estimate on Wall […]
